
MedChemExpress - Model Meseclazone - 29053-27-8
Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.MCE products for research use only. We do not sell to patients.
Meseclazone
MCE China:Meseclazone
Brand:MedChemExpress (MCE)
Cat. No.HY-U00157
CAS:29053-27-8
Synonyms:W2395; NSC297623
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping:Room temperature in continental US; may vary elsewhere.
Description:Meseclazone (W2395;NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.
In Vivo:Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration[1]. Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs caused a dose-dependent inhibition of bronchoconstriction resulting in the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA[2].
Hot selling product:URMC-099 | Stachydrine | Valrubicin | Cenisertib | Oil Red O | GMQ | Filanesib | Ganoderal A | BEBT-908 | AG-09/8
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. Thromb Haemost. 1978 Aug 31;40(1):24-36. [Content Brief]
[2]. Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. Pharmacology. 1982;24(4):243-7. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。